Genetic Analysis Market Report 2026

The genetic analysis market size has grown rapidly in recent years. It will grow from $10.29 billion in 2025 to $11.63 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to limited availability of high-throughput sequencing platforms, reliance on conventional genetic testing methods, growing awareness of genetic disorders, increasing investment in research laboratories, rising number of diagnostic centers.

The genetic analysis market size is expected to see rapid growth in the next few years. It will grow to $18.75 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to advancements in ngs and real-time pcr technologies, development of cloud-based genomic data platforms, increasing adoption of personalized medicine, rising government initiatives for genetic disease screening, integration of ai and bioinformatics tools in diagnostics. Major trends in the forecast period include expansion of next-generation sequencing (ngs) and pcr-based genetic testing, growing adoption of pharmacogenomic testing for personalized medicine, increase in prenatal and newborn genetic screening programs, rising focus on rare disease and cancer genetic diagnostics, integration of bioinformatics and genomic data analysis tools.

The rising incidence of cancer is expected to drive the growth of the genetic analysis market in the coming years. Cancer is a disease in which certain cells grow uncontrollably and can spread to other parts of the body. The number of cancer cases is increasing due to an aging population, as older individuals accumulate genetic mutations and experience prolonged exposure to environmental and lifestyle-related risk factors that contribute to cancer development. Genetic analysis plays a crucial role in cancer management by detecting specific genetic mutations responsible for the disease, enabling physicians to select targeted therapies that are more effective and have fewer side effects. For example, according to a report by the National Cancer Institute (NCI) in May 2025, nearly 20 million people worldwide were newly diagnosed with cancer in 2022, and approximately 9.7 million died from it. Estimates suggest that by 2050, the annual number of new cancer cases could reach 33 million, with deaths expected to rise to 18.2 million. This increasing burden of cancer is therefore fueling the growth of the genetic analysis market.

Key players in the genetic analysis market are focusing on developing advanced solutions, such as genetic testing, to enable early detection and preventive care. Genetic testing involves analyzing an individual’s DNA to identify changes or variations in genes linked to specific health conditions or inherited traits. For instance, in June 2023, Devyser, a Sweden-based diagnostic kit company, launched Devyser LynchFAP and Devyser BRCA PALB2, two genetic testing solutions for hereditary cancer. Devyser LynchFAP provides a comprehensive analysis of PMS2 and nine additional genes associated with hereditary colorectal cancer, addressing the challenge of distinguishing PMS2 from its pseudogene PMS2CL, making it the first commercial kit specifically designed for precise PMS2 analysis. Devyser BRCA PALB2 enables targeted detection of variants in BRCA1, BRCA2, and PALB2, key genes associated with increased breast and ovarian cancer risk. Its user-friendly design allows integration into laboratory workflows and supports analysis of DNA from both blood and tumor samples in a single test.

In February 2025, Tempus AI Inc., a US-based health technology company, acquired Ambry Genetics for an undisclosed amount. This acquisition strengthens the strategic use of diagnostics and data to drive innovation and enhances the ability to deliver advanced genetic analysis solutions to clinicians, patients, and life sciences companies. Ambry Genetics is a US-based provider of genetic analysis solutions.

Major companies operating in the genetic analysis market are Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Quest Diagnostics Inc., Illumina Inc., PerkinElmer Inc., BioRad Laboratories Inc., Qiagen NV, Oxford Nanopore Technologies Plc, 23andMe Inc., ELITech Group, MyHeritage Ltd., Dante Labs Inc., AutoGenomics Inc., IntegraGen SA, Family Tree DNA, 24 genetics, Centrillion Biosciences Inc., DNA Worldwide Group Ltd., Genebase.

North America was the largest region in the genetic analysis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genetic analysis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genetic analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the genetic analysis market by raising costs of imported sequencing instruments, reagents, and bioinformatics software. Segments such as NGS platforms, PCR machines, and DNA/RNA extraction kits are most affected, particularly in regions like North America, Europe, and Asia-Pacific. While tariffs have increased operational costs and slowed equipment procurement, they have also encouraged local manufacturing, innovation in sequencing reagents, and development of domestic bioinformatics solutions, providing long-term opportunities for cost optimization.

The genetic analysis market research report is one of a series of new reports that provides genetic analysis market statistics, including genetic analysis industry global market size, regional shares, competitors with a genetic analysis market share, detailed genetic analysis market segments, market trends and opportunities, and any further data you may need to thrive in the genetic analysis industry. This genetic analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genetic analysis is a scientific technique used to examine deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and chromosomes to understand the structure, function, variation, and inheritance of genetic material. It involves studying genes and their interactions, allowing for the identification of genetic sequences and mutations. By analyzing genetic patterns and inheritance, this process provides insights into biological functions and hereditary traits.

The primary products of genetic analysis include reagents and kits, instruments, and software. Reagents and kits consist of chemical substances and prepared solutions used to carry out specific biological reactions or laboratory processes. Genetic analysis offers a variety of tests, including predictive genetic testing, carrier testing, prenatal and newborn testing, disease diagnostic testing, pharmacogenomic testing, and more. It employs different technologies such as next-generation sequencing (NGS), real-time PCR systems, and others. These products are applied across multiple areas, including cancer, genetic disorders, cardiovascular diseases, rare diseases, and infectious diseases, and serve a range of end users, including hospitals, research and development laboratories, diagnostic centers, and others.

The genetic analysis market consists of revenues earned by entities by providing services such as bioinformatics analysis, transcriptome analysis, microarray analysis services, and custom assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. The genetic analysis market also includes sales of genotyping arrays, library preparation kits, gene expression assays, and microarray slides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.